NovoCure Limited

NovoCure Limited

10.53
EUR
-0.02
(-0.19%)
-0.94EPS
Feb 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.14
0.21
1.09
0.97
2
2.7
3.61
4.9
5.17
5.14
4.79
5.61
5.88
6.32
Basic EPS, GAAP
-1.07
-1.12
-3.67
-1.54
-0.7
-0.69
-0.07
0.2
-0.56
-0.88
-1.95
-1.56
-1.22
-1.06
Free Cash Flow per Basic Share
-0.78
-1.06
-3.62
-1.46
-0.46
-0.09
0.17
0.83
0.57
0.09
-0.94
-0.64
-0.68
-0.21
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.08
1.18
2.99
1.63
1.27
1.2
2.19
4.66
3.95
4.2
3.39
3.32
3.03
3
Tangible Book Value per Share
2.08
1.18
2.99
1.63
1.27
1.2
2.19
4.66
3.95
4.2
3.39
3.32
3.03
3
Basic Weighted Avg Shares
72
72
30
86
89
92
97
101
103
105
106
108
111
115
Sales/Revenue/Turnover
10
15
33
83
177
248
351
494
535
538
509
605
655
725
Operating Margin (%)
-622.25
-517.47
-314.31
-139.12
-22.22
-13.57
-0.26
6.15
-8.29
-16.64
-45.72
-28.17
-23.47
-17.17
Depreciation Expense
1
2
3
6
8
9
8
9
10
11
11
11
15
17
Net Income, GAAP
-77
-81
-112
-132
-62
-64
-7
20
-58
-93
-207
-169
-136
-122
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-746.89
-520.87
-337.24
-159.06
-34.83
-25.62
-2.06
4.01
-10.91
-17.2
-40.65
-27.86
-20.79
-16.78
Working Capital
168
94
265
225
195
257
354
886
931
953
855
350
424
403
LT Debt
- -
- -
23
97
98
149
164
444
575
584
596
117
237
207
Total Equity
172
98
251
142
114
112
218
477
410
441
362
360
340
351
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-59.84
-64
-67.07
-48.19
-56.29
-4.38
5.71
-13.16
-21.73
-51.52
-46.67
-38.89
-35.18

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
25
LT Borrowings
195
196
171
LT Finance Leases
39
38
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
116
116
117
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
632
639
674
Cash, Cash Equivalents & STI
432
441
463
Accounts Receivable, Net
93
91
108
Inventories
43
42
41
Total Current Liabilities
218
221
271
Payables & Accruals
218
221
246
ST Debt
- -
- -
25
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.79%
-6.07%
-5.47%
Free Cash Flow
-130.02%
-260.21%
9.32%
Net Income, GAAP
-74.46%
-50%
-19.21%
Sales/Revenue/Turnover
41.71%
6.11%
8.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
139
150
155
161
605
2025
155
159
167
174
655
2026
174
184
193
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
-0.31
-0.28
-0.61
-1.56
2025
-0.31
-0.36
-0.33
-0.22
-1.22
2026
-0.62
-0.13
-0.09
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Frank Leonard
Full Time Employees
1,605
Sector
Health technology
Industry
Medical specialties
Address
Neuhofstrasse 21 St. Helier United Kingdom 6340
IPO Date
Oct 2, 2015
Business
NovoCure Limited (Nasdaq: NVCR) is a global oncology company that develops, manufactures and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive anti-mitotic treatment delivered via wearable devices that disrupt cancer cell division in solid tumors. Its main commercialized products include Optune Gio, approved for adult patients with glioblastoma (GBM), and Optune Lua, approved for malignant pleural mesothelioma (MPM); in 2024, the U.S. FDA expanded approvals to include TTFields therapy concurrently with PD-1/PD-L1 inhibitors or docetaxel for metastatic non-small cell lung cancer (mNSCLC) following platinum-based therapy, and approved new Head Flexible Electrode (HFE) transducer arrays to enhance patient comfort in GBM treatment. The company conducts Phase 3 clinical trials such as PANOVA-3 (pancreatic cancer), LUNAR-2 and METIS (lung and brain metastases), and TRIDENT (ovarian cancer), targeting additional aggressive cancers. Founded in 2000 and headquartered in Baar, Switzerland, with U.S. operations in Portsmouth, New Hampshire, and R&D in Haifa, Israel, NovoCure operates in the United States, Germany, France, Japan, Greater China and other international markets. Recent developments include the January 2025 inauguration of new global headquarters in the Canton of Zug, Switzerland, to support expansion; a multi-tranche $400 million non-dilutive debt financing with Pharmakon Advisors, with $100 million drawn at closing and more available through 2025; and positive topline results from the Phase 3 PANOVA-3 trial demonstrating statistically significant overall survival improvement in unresectable pancreatic cancer.

Company News

  • JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

  • FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

  • Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

  • Head-To-Head Contrast: Flora Growth (NASDAQ:FLGC) & NovoCure (NASDAQ:NVCR)

  • Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock

  • NovoCure: 3 Key Takeaways for Long-Term Investors

  • NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript

  • NovoCure Q3 Earnings Call Highlights

  • NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

  • Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

  • Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

  • NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast

  • Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

  • Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)

  • Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)

  • Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

  • NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LP

  • NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

  • NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • Novocure Reports Patient Data Exposure in Cybersecurity Incident